Amgen to acquire deCODE Genetics
10 December 2012 | By Amgen
Amgen and deCODE Genetics announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics...
List view / Grid view
10 December 2012 | By Amgen
Amgen and deCODE Genetics announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics...
12 November 2012 | By Amgen
Amgen and Pfizer announced that results from several Enbrel® (etanercept) studies...
5 November 2012 | By
Results from RUTHERFORD study presented at American Heart Association Scientific Sessions 2012...
3 November 2012 | By Amgen
Study results presented at American Society of Nephrology's Kidney Week...
2 November 2012 | By Amgen
Amgen to present data from four Phase 2 trials...
14 October 2012 | By Amgen
Data from several Prolia® studies...
12 October 2012 | By Amgen
Amgen has announced the appointment of Cynthia M. Patton...
20 September 2012 | By Amgen
A new indication for Prolia® approved...
10 September 2012 | By Amgen
Amgen announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs...
8 August 2012 | By Amgen
Amgen announced a decision to stop the ganitumab Phase 3 GAMMA trial...
In this PAT In-Depth Focus: Process analytics experiences in biopharmaceutical manufacturing; Correlation between powder rheology data and processability in solid dosage form manufacturing; Expert industry users of process analytical technologies for pharmaceuticals pose questions for leading vendor experts of process analytical technology...
5 July 2012 | By Amgen
Amgen has announced the completion of the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco...
12 June 2012 | By Amgen
Amgen announced the completion of the acquisition of more than 99 percent of the shares of Mustafa Nevzat Pharmaceuticals...
8 June 2012 | By Amgen
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...
16 May 2012 | By Amgen
Updated results from a Phase 2 study...